Chimeric cohorts and consortia can power and scale precision medicine

Patrick J. Silva, Nancy K. Sweitzer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Precision medicine practice requires an understanding of the similarities and difference between disease processes in individuals. To test a hypothesis or validate a biomarker in a retrospective study inherently requires clear criteria to define the disease state. The large datasets required for current “omics” analyses often require building cohorts from multiple sources of specimens, data, or patients. The disposition of research work product often carries implications of data governance, intellectual property rights, and commercial revenue that can derail well-intentioned and well-designed studies. Increasingly, stakeholders in the process are focused on nonscientific considerations that are not tractable with scientific tools but require scientific understanding to solve. In this chapter, we provide a number of vignettes illustrating the opportunities and challenges inherent in building such chimeric cohorts across organizational boundaries and showcasing tools useful in building fit-for-purpose collaborations that can satisfy scientific, clinical, ethical, and commercial objectives.

Original languageEnglish (US)
Title of host publicationComprehensive Precision Medicine, First Edition, Volume 1-2
PublisherElsevier
PagesV2-264-V2-282
Volume1-2
ISBN (Electronic)9780128240106
DOIs
StatePublished - Jan 1 2023
Externally publishedYes

Keywords

  • Biorepository
  • Cardiology
  • Cardiomyopathy
  • Chronic disease
  • Clinicogenomic
  • Data governance
  • Data sharing
  • Genome-wide association studies
  • Genomics
  • Next generation sequencing
  • Pharmacogenomics
  • Precision medicine
  • RNAseq
  • Real-world data

ASJC Scopus subject areas

  • General Agricultural and Biological Sciences
  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Chimeric cohorts and consortia can power and scale precision medicine'. Together they form a unique fingerprint.

Cite this